NVO:NYSENovo Nordisk A/S analysis
Data as of Oct 13, 2026 - not real-time
- Latest price
- $38.06
- Risk: medium
- 6/10Medium risk
Summary
The moving-average structure behind Novo Nordisk A/S is bearish at $38.06, with short-term averages lagging the long-term ones. The last 30 days have lost 16.0%. Momentum indicators put RSI at 35.1 (approaching oversold) with MACD reading bullish. Watch $36.85 as support and $43.54 as the nearer resistance level.
The shares look undervalued, trading on 9.3 times earnings below a sector average of 30.3. Analyst price targets sit 19.6% above the current price. Revenue is growing at 2.1% on a 35.3% profit margin. The 4.66% dividend yield looks covered by current payout levels.
The composite risk read is 6/10, putting it in elevated territory. With 30-day volatility of 35.0%, a beta of 1.04 and a maximum drawdown of 44.8%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 4 out of 10.
The shares look undervalued, trading on 9.3 times earnings below a sector average of 30.3. Analyst price targets sit 19.6% above the current price. Revenue is growing at 2.1% on a 35.3% profit margin. The 4.66% dividend yield looks covered by current payout levels.
The composite risk read is 6/10, putting it in elevated territory. With 30-day volatility of 35.0%, a beta of 1.04 and a maximum drawdown of 44.8%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 4 out of 10.
Top market events
- Novo Nordisk NYSE:NVO did something this year that usually pleases investors: it raised its full-year outlook.
- A stock that has lost more than 70% of its value from the peak tends to invite hard questions, and Novo Nordisk A/S...
- Two of the world's most closely watched pharmaceutical companies are drawing fresh scrutiny from investors seeking...
Market outlook
Short term
< 1 yearNeutral
Model confidence1/101 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 45.26
- MACD momentum is positive
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- P/E of 9.3 versus sector average of 30.3
- Trading below the 200-day average of 45.26
Long term
> 3 yearsPositive
Model confidence4/104 out of 10
Key factors
- P/E of 9.3 versus sector average of 30.3
- Analyst targets imply +19.6% versus the current price
- Profit margin of 35.3% is healthy
Key metrics
Financial health
Revenue Growth2.10%
Profit Margin35.35%
P/E Ratio9.3
ROE59.81%
ROA18.73%
Debt/Equity63.33
P/B Ratio5.1
Op. Cash Flow$131.9B
Free Cash Flow$37.7B
Industry P/E30.3
Technical analysis
TrendBearish
RSI35.1
Support$36.85
Resistance$43.54
MA 20$38.97
MA 50$43.08
MA 200$45.26
MACDBullish
VolumeDecreasing
Fear & Greed Index94.16
Valuation
Fair Value$89.59
Target Price$45.53
Upside/Downside19.62%
GradeUndervalued
TypeValue
Dividend Yield4.66%
Risk assessment
Beta1.04
Volatility35.03%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.